Ana Almonte-Loya

Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis

Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, is driven by an overactive immune signaling pathway called type I interferon. Current treatment relies on broadly immunosuppressive agents that lack mechanistic specificity, often fail to achieve durable disease control, and can result in...